Characteristics of long-term survivors with Myelodysplastic syndrome treated with 5-azacyditine. Results from the Hellenic 5-azacytidine Registry.

Hypomethylating agents have altered the prognosis of myelodysplastic syndrome (MDS) so that long-term survival is now a feasible goal of treatment.We analyzed data from patients with MDS treated with 5-azacytidine recorded in the Hellenic 5-azacytidine registry. We divided patients, based on their survival after 5-azacytidine initiation (OST), in groups of long-term survivors (Q3 and P90 group with OST above the 3rd quartile and the 90th percentile of the whole group, respectively) and short-term survivors comprising the remaining patients, and compared the characteristics between the groups.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 27, 2019 Category: Hematology Authors: Panagiotis T. Diamantopoulos, Vasiliki Pappa, Argiris Symeonidis, Ioannis Kotsianidis, Athanasios Galanopoulos, Helen Papadaki, Achilles Anagnostopoulos, George Vassilopoulos, Panagiotis Zikos, Eleftheria Hatzimichael, Maria Papaioannou, Aekaterini Megala Tags: Original Study Source Type: research